Ultima Genomics partners with New England Biolabs® to expand research applications on Ultima Sequencers

Ultima Genomics, Inc., a developer of a revolutionary new ultra-high throughput sequencing architecture, today announced a collaboration to develop and enable use of New England Biolabs’ (NEB®) NEBNext® reagents and library preparation kits on Ultima sequencing platforms. As part of the collaboration, the parties will develop optimized next generation sequencing (NGS) workflows to support DNA, RNA, and methylation sequencing applications.

An important initial step in successful NGS is high quality and consistent library preparation. The NEBNext portfolio supports an extensive array of NGS applications, from PCR-free whole genome analysis to RNA- and methylation-sequencing, and are designed to provide the highest quality reagents and libraries using streamlined workflows from a broad range of inputs.

This collaboration demonstrates our commitment to provide high performance end-to-end workflows to our customers. We are excited to leverage NEB’s success in delivering high quality molecular biology reagents and library preparation products, together with Ultima’s innovative sequencing technologies to enable new insights and discoveries by our mutual customers.”

Doron Lipson, Chief Scientific Officer, Ultima Genomics.

We’re excited to see the Ultima Genomics platform be adopted by scientists to help solve important problems. Ensuring that NEBNext reagents are positioned to address a broad range of sample preparation applications upstream of the Ultima Genomics platform will enable users to experience the quality reagents and innovative approaches that they have come to expect from NEBNext. We look forward to the scientific discoveries that will result from this collaboration.”

Fiona Stewart, Associate Director of NGS Portfolio Management, NEB.

Scientists and researchers interested to learn more about NEBNext reagents and library preparation workflows on Ultima Genomics sequencing platforms can find more information at https://www.ultimagenomics.com/publications-and-resources as well as https://www.nebnext.com

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Ultima Genomics, Inc.. (2023, February 16). Ultima Genomics partners with New England Biolabs® to expand research applications on Ultima Sequencers. News-Medical. Retrieved on June 17, 2024 from https://www.news-medical.net/news/20230216/Ultima-Genomics-partners-with-New-England-Biolabsc2ae-to-expand-research-applications-on-Ultima-Sequencers.aspx.

  • MLA

    Ultima Genomics, Inc.. "Ultima Genomics partners with New England Biolabs® to expand research applications on Ultima Sequencers". News-Medical. 17 June 2024. <https://www.news-medical.net/news/20230216/Ultima-Genomics-partners-with-New-England-Biolabsc2ae-to-expand-research-applications-on-Ultima-Sequencers.aspx>.

  • Chicago

    Ultima Genomics, Inc.. "Ultima Genomics partners with New England Biolabs® to expand research applications on Ultima Sequencers". News-Medical. https://www.news-medical.net/news/20230216/Ultima-Genomics-partners-with-New-England-Biolabsc2ae-to-expand-research-applications-on-Ultima-Sequencers.aspx. (accessed June 17, 2024).

  • Harvard

    Ultima Genomics, Inc.. 2023. Ultima Genomics partners with New England Biolabs® to expand research applications on Ultima Sequencers. News-Medical, viewed 17 June 2024, https://www.news-medical.net/news/20230216/Ultima-Genomics-partners-with-New-England-Biolabsc2ae-to-expand-research-applications-on-Ultima-Sequencers.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.